ANP32A

Across TCGA pan-cancer cohorts, ANP32A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANP32A data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ANP32A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANP32A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where ANP32A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.459	0.957	.007	18	view →
HNSC	OS	Quartile	All	0.777	0.925	.015	13	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	9	view →
CCRCC	DFS	Tertile	II,III,IV	0.712	0.260	.042	1	view →
GBM	OS	Median	All	0.452	0.288	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANP32A–LUAD (DFS)

Open the LUAD breakdown →